R
Ralf Gutzmer
Researcher at Hannover Medical School
Publications - 452
Citations - 27935
Ralf Gutzmer is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 62, co-authored 375 publications receiving 21291 citations. Previous affiliations of Ralf Gutzmer include Hochschule Hannover & Université Paris-Saclay.
Papers
More filters
Journal ArticleDOI
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Wilson H. Miller,Eckhart Kaempgen,Salvador Martín-Algarra,Boguslawa Karaszewska,Cornelia Mauch,Vanna Chiarion-Sileni,Anne-Marie Martin,Suzanne Swann,Patricia Haney,Beloo Mirakhur,Mary E. Guckert,Vicki L. Goodman,Paul B. Chapman +20 more
TL;DR: Dabrafenib significantly improved progression-free survival compared with dacarbazine, and skin-related toxic effects, fever, fatigue, arthralgia, and headache were uncommon in both groups.
Journal ArticleDOI
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S. Weber,Sandra P. D'Angelo,David R. Minor,F. Stephen Hodi,Ralf Gutzmer,Bart Neyns,Christoph Hoeller,Nikhil I. Khushalani,Wilson H. Miller,Christopher D. Lao,Gerald P. Linette,Luc Thomas,Paul Lorigan,Kenneth F. Grossmann,Jessica C. Hassel,Michele Maio,Mario Sznol,Paolo A. Ascierto,Peter Mohr,Bartosz Chmielowski,Alan H. Bryce,Inge Marie Svane,Jean-Jacques Grob,Angela M. Krackhardt,Christine Horak,Alexandre Lambert,Arvin Yang,James Larkin +27 more
TL;DR: Nivolumab led to a greater proportion of patients achieving an objective response and fewer toxic effects than with alternative available chemotherapy regimens for patients with advanced melanoma that has progressed after ipilimumab or ipilicumab and a BRAF inhibitor.
Journal ArticleDOI
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen,Eliezer M. Van Allen,Diana Miao,Diana Miao,Bastian Schilling,Sachet A. Shukla,Sachet A. Shukla,Christian U. Blank,Lisa Zimmer,Antje Sucker,Uwe Hillen,Marnix H Geukes Foppen,Simone M. Goldinger,Jochen Utikal,Jochen Utikal,Jessica C. Hassel,Benjamin Weide,Katharina C. Kaehler,Carmen Loquai,Peter Mohr,Ralf Gutzmer,Reinhard Dummer,Stacey Gabriel,Catherine J. Wu,Catherine J. Wu,Dirk Schadendorf,Levi A. Garraway,Levi A. Garraway +27 more
TL;DR: Investigating the roles of tumor-specific neoantigens and alterations in the tumor microenvironment in the response to ipilimumab found no recurrent neoantigen peptide sequences predicted responder patient populations, suggesting detailed integrated molecular characterization of large patient cohorts may be needed to identify robust determinants of response and resistance to immune checkpoint inhibitors.
Journal ArticleDOI
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont,Christian U. Blank,Mario Mandalà,Georgina V. Long,Victoria Atkinson,Stéphane Dalle,Andrew Haydon,Mikhail Lichinitser,Adnan Khattak,Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,James Larkin,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Rutkowski,Dirk Schadendorf,Rutger H. T. Koornstra,Leonel Hernandez-Aya,Michele Maio,Alfonsus J. M. van den Eertwegh,Jean-Jacques Grob,Ralf Gutzmer,Rahima Jamal,Rahima Jamal,Paul Lorigan,Nageatte Ibrahim,Sandrine Marreaud,Alexander C.J. van Akkooi,Stefan Suciu,Caroline Robert +31 more
TL;DR: As adjuvant therapy for high‐risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence‐free survival than placebo, with no new toxic effects identified.
Journal ArticleDOI
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen,Eliezer M. Van Allen,Nikhil Wagle,Nikhil Wagle,Antje Sucker,Daniel J. Treacy,Cory M. Johannessen,Eva M. Goetz,Chelsea S. Place,Chelsea S. Place,Amaro Taylor-Weiner,Steven R. Whittaker,Gregory V. Kryukov,Eran Hodis,Eran Hodis,Eran Hodis,Mara Rosenberg,Aaron McKenna,Aaron McKenna,Kristian Cibulskis,Deborah N. Farlow,Lisa Zimmer,Uwe Hillen,Ralf Gutzmer,Simone M. Goldinger,Selma Ugurel,Helen Gogas,Friederike Egberts,Carola Berking,Uwe Trefzer,Carmen Loquai,Benjamin Weide,Jessica C. Hassel,Stacey Gabriel,Scott L. Carter,Gad Getz,Gad Getz,Levi A. Garraway,Levi A. Garraway,Levi A. Garraway,Dirk Schadendorf +40 more
TL;DR: A "long tail" of new mitogen-activated protein kinase (MAPK) pathway alterations (MAP2K2, MITF) that confer RAF inhibitor resistance are discovered that may model subsequent resistance studies of BRAF(V600)-mutant melanoma.